pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-3194 |
Genomic Coordinates | chr20: 51452905 - 51452977 |
Description | Homo sapiens miR-3194 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |||||||
---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-3194-5p | ||||||
Sequence | 10| GGCCAGCCACCAGGAGGGCUG |30 | ||||||
Evidence | Experimental | ||||||
Experiments | Illumina | ||||||
SNPs in miRNA |
|
||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SFMBT2 | ||||||||||||||||||||
Synonyms | - | ||||||||||||||||||||
Description | Scm like with four mbt domains 2 | ||||||||||||||||||||
Transcript | NM_001029880 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SFMBT2 | |||||||||||||||||||||
3'UTR of SFMBT2 (miRNA target sites are highlighted) |
>SFMBT2|NM_001029880|3'UTR 1 GTCTGCCCTCGGGAGGTGGCCCATTATTGCTGGGATGCGGTGTTGGTAAAGGTTTCCAGGACTGAAACTTTGATTTTCCG 81 GGATATGTTAAATGGTACAGCCACTAAGTATCACCAGAAAACCAGAAGCCCAGGATCTTCTGCCTCCGCCAGCCTGTGAG 161 CTGTTTCCATGTTTTCAAAGCACAGCAGCAGTCGCTTCTGGGGAGTGCCAGTTAAAGTCATGCATCAGACCCTGCCAGAC 241 GTGGGCCTGCTTCTTGGCTCACCCACGTTTTGCCTTTCTCCTGCCCCAAATCAGGCAGCTCCCTTGGAGCAGGGTTTCCT 321 CAGATGAGGACTGCATTCTTTGAAAACAAAGAATGTCGCCAAGGAAGAAACCTCACGCCATGCTGTAGTGTTTCCTGTAA 401 TCACACGAGCACATTTATATATGCAGTTTCCCATGGATAGGCGTGTGACCCTGGTTGAGTGGCACTTGCGGTTTCATCTT 481 GGTGGCAACTCCTTTGCAATGCAGCTGGCAGCGACATCCTTATAAAAACATGTGCTAAAGCTCTGTCCTCTGTTAGAGGT 561 GCCTTTTAGGAATACGGGGAGTGAAGGAAGGCCGGCAGGCATCTCCATGCAACTAGATGGTTTGTTTGTTTGTTTGTTTG 641 TTTGTTGTTCATTTTGTTGTGTTTTTTGAGACAGGGTCTTGCTCTGTCGCCCAGGTTGTAATGCAGTGGCGCAATCTCAG 721 CTCACTGCAACCTCTCTCTCCCGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGATTACAGGCACCCAC 801 CACCATGCCTGGCTAATTTTTGTATTTTTGGTAGAGACAGGGTTTCACCATGTTGGTCAGGCTAGTCTTGAACTCCCAAC 881 CTCAAGTGATCTGCCCGCCTCGGCCTCCCAACGTGCTGGGATTACAGGTGTGAGCCACTACGCCCCGGCCCAACTGGATG 961 GTTTTTGATTGAAGCCTAGAACATCTGTAGAGACAAACTCTACCCAGTCTTTTCTAGACCCTCAACTATCTCCAGTGTTG 1041 TTGTTTAATCGTAGCCGGATCAGGGAGTGAGTCTTTTAGGCAAATGTTGGATTATATATCAAAGGAAAAGCTTAGTTTCA 1121 GAGAGGAGGAAGGGAAAGAGATGTGAGGGAAGCATTTCATCAACCAGCTACGTCCCCCTTAGAAGGATCACTGCAGCAGG 1201 TCACCGAGCAGGAGTCCCTCTGAGCGTCCCTTCTGTCTCGTTCTGCCCTAGCTGGCAGCATATGAACCAGGCATGATGCA 1281 GCAGGAGCAGTGAATCTGGAGTCAGCCACTTGGCACCCTGGTTTCGCTGAGAACAAACTCTGAGATCTTGGGTGACTTCT 1361 CATCACTCTGGACCTCCATTCCTGTGAAGTGACAGGTGTGGACCCTGAGGGTGCGGTGGTGAGCACACTGTCTCCTGCTG 1441 GCATTCACCCCACTCATGCTGGAAAGGAAGATCCAGATCGTACAAAAATTAGAAAAAGAAAGAATAAGAAGGGTCTGGTC 1521 CCAGTTCTGACTCGGCCATTCTTACAGCTCTTTCTGGCTTTGAGTTTGCTTGTGGAATTTCCTGGGCAGTTGTGTTAAAT 1601 CCGCCAGGTCACGTGCAGACAAAGCTGTGGCTGCGAGAGTTGGCTGGCCTCTTGGACCAGAAGCCATCTCCATATCCTCA 1681 TGAGCGATTCCATATCTCCACTCAGACCCTGTGGACTACAGTGTTCCGCTGTGGTGGCTGCCAAGATGCCTTCTTAAACT 1761 TATGCAAGGAAACCAAACCCTCCCACAGTTCCCAAGCAGACACTGGAAGCAGAGGCTTCTCACCCTTCCTGCTTTTTCAC 1841 CACAATCACCTTGAGCTCGTCCCTTGGACTAGAGTCTCCACAGTTCCAGTAAAATTCTGCGGTGGGCTGATGAGCTGCTT 1921 GCATTTCTGTGACATTTCCAGATATGATTCTCAGTGGGATTTTGGAAACTTTGATTGCTCAAGCTCACCCTTCTTAACAT 2001 TCTGTAATGGTTACAGATGAGAATGGAAAACACATATTTTATGGATGAGGCGTTTTGGTCTCCCCTGCAGTCGATTTCTA 2081 GAATCAAGTTTTAGAGTTCGGCTGATGCATCTGCCTGGGGACCTCAGATGGGAGGAGTGTGTCAGTTGTACCCCGACAGA 2161 AATGTCTCTGGGATCTGTGGCTGGCTTGCCCCGGGCATCTCTCCTTTAAGCTCAAGTTTTGAACTCTCTGCGGTTTTCCA 2241 CCCCTGCCTTCTCAGCCACATGCTTTTGGCCTTAAACGCTCAGTCTTGTGGAGTTCAACTCTGTCAAACGATTGGAAAGG 2321 GCATCCATTTCCAGATCTTTGGCATTTTCCCCGCGCTGACTCTTTGATGATCCTTCACTGTGGCCTTTTCAAGCTCAGCT 2401 GTTCCTGTTGTATTTGAGACGAGGGTGAGGGAATGTGGTGGCCACAAAAGAACAGGGACTTGCAGCACAAATGTCACTTC 2481 TGTCTCCCTTTTCAGTGGTAGCACGGAGGAGGAGGTGCTGCGTTGGAGGGAGGGGATCCTCCAGGAGCTCTCTGGAGCCC 2561 ATCTAGGAAGCTAGAGTGTGTGGCCCGCCAGGAGCTCAGGAAGGATACAGCCACTGTCGCAGGGGAAAGTGTTTGCTTCC 2641 CGTGGAGCCAAGCGCCCAAGACTCTCCGTATCCTTCACCCTGACAGTTTAACTTCAGCGTTTCTCTGTGCAGTTGCGGTC 2721 ACCATGGGTGAGCACTGTCTGTGCACGTGCCAGGGAGGAGATGGCTGGGACCACTGCACAGGAGGGCGCAGCCTGGCGTC 2801 GCCATGAAAGTTGTCTCTGTGCCATCTCTCCGGTCCTTGAGGAGAGCCCAGAAAGATTTTAGGACCCAGGAGGTGCTTTT 2881 CCTCCAGCTGTTGCCAGTGTCCTTCTGAGCCTGGATTCTCCGGGGATTTCCGTCGTGGTGGATGGACTTCACATCAGCAG 2961 CAGTTCTGGTACAGAATTGTAATGTGTTTTCATTTCTCTGTAGGATTCACCTCTCACCAGCGTCTGTCTTAAAGGTAGGG 3041 CCAATTTCATGGAGCATTTTTCTGTGTGTGTCCTTGTTGCTTTTGCCAGAAAAAGTGGATTTGACATGCGTGCCCCGATG 3121 CCACCATAGCCCCTAGGCCAACAATGTCATGGTCTAAACACCAAAAAGTGATGCCCCGCATTCCTTCCCTGGATGGTACC 3201 GTTTCTTCTCCGTCTCTCTTTGATGATTCTTTGGGACCAAAGTCCTCTCCTTAGTGCGCCTACTTCCTGTGGGCATCATG 3281 CCACTTGGAACTTATTGGAACTGGCCCGGGAGACTCTGCAGTCTGCGCCGTTTGAAAACCCTGAGAAAGAGATGCCACCT 3361 CAACTTGAATCATGACAGCCCATCGCTCAGTCTCACCCTAAACTCATGGAGCTTGTTTCAGCTCCTCACTTCTTGACTGT 3441 ATTTGTACTATGTTGAAAAAATATCCTGTCCACAAAGACATAAGCCTAACAACCTAGAAAAACAACAGGGTACTACTGGC 3521 ATTACAGAACTTCTTTGCCTTTCAAAACAAAAGCAAAACACAGTGAACTTCACCACGGAGCTGCACAGCGTGGGGAACTC 3601 ATCCATCACTTTCAAAATTAGAGTCATTTGATCCAAGTTGGAGTCAGACACAGTATTTGAGCTGCACGGCTTCTGGGTTC 3681 TCCCACCTTATTTGATCATATTCGAAAGATTATTTCCTGTGTTTGCTTTGATTTGTTCCTCAGTACATTAAAATGATCCA 3761 CACCTTGAACACTGCCCTCTCTAGAAGGTTGATTTTGATCAGCCTTTTGAAGATGGGTGTCGTTTCCCTAACTTATCTCA 3841 CAGAATTTTGAGTGTTGTATTTGGCAAGTTCTGAGATTTGCCTTCTGTCTTATGCCAAACACCCCTTTCTAAGAGCTGTC 3921 CCCGCTTAGTTTTAGAAGTACTAGGGGTTTTCATACTTATTTTATAGAACACCCATTTATATTTATTTCTGTATATAGAA 4001 CTAAAAAAAACAGTAGTGTTAAAAATCTTTGTTGTGGTTTGAGCATCTTTGCTGCTTTTGGATTGAGATGGCGAATCAAG 4081 GCTTCACTTCCTCTCTCTTCTGTCTTTAGAAAGCTGTGATCGTGCGTGCAATTATTTGAAAGGCAACATAGTCAATTAAG 4161 AAACCTGTAGTTGTTAAGGAAGAAATTGTTGGCAAGATATCCATACTGCCCATATCTCGTTGGTGCAATAATTAAATAGC 4241 AAAGGAAATCTGTATTGGCAACTATTATAATTCAATAATTCTTTTGTTTACTGCCCTTTTCTGTTCAAGAATTTTCTGGA 4321 AATTACTCCCTTTCACATGGTTGAACTCTTAAGTTGACCAGTTCTCATAGCTCTATCACTAGAATGGTTTGCAGATACCC 4401 CAAACATACTATGATAAAATCAAATTGTGCTACTTTTGACCCATGTAATTTACCTAAAAGTTGTAATTGCTGACAGAGTA 4481 CTGCCTTGAATTTTGGTTTAAAACCTCTCTAGTTTCAATGACAAGTAACAACTCAAATAATTCCATATTGTTTGAGGAAG 4561 AGGCCATAATCCTTCTGAATTGTTGGCACTAAGTAATGGGATTTGGCCCAGTAAGTATGACGGTCGTGTCGCCTAACCAA 4641 CGCAGAGCAGTGCTTTTTGTGTGGCTGAAGCGATGTGCTGACGAAAAAAGGAAAATTCTAGGACAATCGTTGGCTAAAAA 4721 TCACCTTAGGATGAAAAATTTGAGGCAAATTTTTTTAAATGACAGAAAAAGATAATCATCTCACTTGCTTGAAACAGGAG 4801 CCAGCATGATCTCTGGAAGCATCAACTATCCCTCGTCGTGATTGTTGAAAGCTCTTTCACTGTTTTGCATTCTAGTTTGA 4881 ATAGTTTGTATTGAAATTGGATTCCTATCTTGTGTATGTTTTTGGTGCGTAAAAGGGAAAAATTGGTGTCATTACTTTTG 4961 AAATTTGCAGGACGAAGGGCATGCTTTTGGTTTGCTGTAAGATTGTATTCTGTATATATGTTTTCATGTAAATAAATGAA 5041 AATCTATATCAGAGTTATATTTTAATTTTTATTCTAAATGAAAAAAACCCTTTTTACTTCAAAAAAATTGTAAGCCACAT 5121 TGTTAATAAAGTAAAAATAAATTCTA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | hESCs (WA-09) | ||||||
Disease | 57713.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in SRR359787. RNA binding protein: AGO2. Condition:4-thiouridine
... - Lipchina I; Elkabetz Y; Hafner M; Sheridan et al., 2011, Genes & development. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Lipchina I; Elkabetz Y; Hafner M; Sheridan et al. - Genes & development, 2011
MicroRNAs are important regulators in many cellular processes, including stem cell self-renewal. Recent studies demonstrated their function as pluripotency factors with the capacity for somatic cell reprogramming. However, their role in human embryonic stem (ES) cells (hESCs) remains poorly understood, partially due to the lack of genome-wide strategies to identify their targets. Here, we performed comprehensive microRNA profiling in hESCs and in purified neural and mesenchymal derivatives. Using a combination of AGO cross-linking and microRNA perturbation experiments, together with computational prediction, we identified the targets of the miR-302/367 cluster, the most abundant microRNAs in hESCs. Functional studies identified novel roles of miR-302/367 in maintaining pluripotency and regulating hESC differentiation. We show that in addition to its role in TGF-beta signaling, miR-302/367 promotes bone morphogenetic protein (BMP) signaling by targeting BMP inhibitors TOB2, DAZAP2, and SLAIN1. This study broadens our understanding of microRNA function in hESCs and is a valuable resource for future studies in this area.
LinkOut: [PMID: 22012620]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | C8166 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462572. RNA binding protein: AGO2. Condition:C8166 NL4-3
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HCT116 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in ERX177603. RNA binding protein: AGO2. Condition:p53_D_AGO_CLIP_2_5
PAR-CLIP data was present in ERX177599. RNA binding protein: AGO2. Condition:p53_D_AGO_CLIP_2_1
PAR-CLIP data was present in ERX177611. RNA binding protein: AGO2. Condition:p53_D_AGO_CLIP_3_1
PAR-CLIP data was present in ERX177615. RNA binding protein: AGO2. Condition:p53_D_AGO_CLIP_3_5
PAR-CLIP data was present in ERX177623. RNA binding protein: AGO2. Condition:p53_D_AGO_CLIP_4_1
PAR-CLIP data was present in ERX177627. RNA binding protein: AGO2. Condition:p53_D_AGO_CLIP_4_5
... - Krell J; Stebbing J; Carissimi C; Dabrowska et al., 2016, Genome research. |
Article |
- Krell J; Stebbing J; Carissimi C; Dabrowska et al. - Genome research, 2016
DNA damage activates TP53-regulated surveillance mechanisms that are crucial in suppressing tumorigenesis. TP53 orchestrates these responses directly by transcriptionally modulating genes, including microRNAs (miRNAs), and by regulating miRNA biogenesis through interacting with the DROSHA complex. However, whether the association between miRNAs and AGO2 is regulated following DNA damage is not yet known. Here, we show that, following DNA damage, TP53 interacts with AGO2 to induce or reduce AGO2's association of a subset of miRNAs, including multiple let-7 family members. Furthermore, we show that specific mutations in TP53 decrease rather than increase the association of let-7 family miRNAs, reducing their activity without preventing TP53 from interacting with AGO2. This is consistent with the oncogenic properties of these mutants. Using AGO2 RIP-seq and PAR-CLIP-seq, we show that the DNA damage-induced increase in binding of let-7 family members to the RISC complex is functional. We unambiguously determine the global miRNA-mRNA interaction networks involved in the DNA damage response, validating them through the identification of miRNA-target chimeras formed by endogenous ligation reactions. We find that the target complementary region of the let-7 seed tends to have highly fixed positions and more variable ones. Additionally, we observe that miRNAs, whose cellular abundance or differential association with AGO2 is regulated by TP53, are involved in an intricate network of regulatory feedback and feedforward circuits. TP53-mediated regulation of AGO2-miRNA interaction represents a new mechanism of miRNA regulation in carcinogenesis.
LinkOut: [PMID: 26701625]
|
CLIP-seq Support 1 for dataset SRR359787 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | hESCs (WA-09) / 4-thiouridine, RNase T1 |
Location of target site | ENST00000361972.4 | 3UTR | CACACUGUCUCCUGCUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22012620 / SRX103431 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1462572 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | C8166 / C8166 NL4-3 |
Location of target site | ENST00000361972.4 | 3UTR | CACACUGUCUCCUGCUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
72 hsa-miR-3194-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT443250 | C9orf170 | chromosome 9 open reading frame 170 | 2 | 2 | ||||||||
MIRT443284 | ZC3H12A | zinc finger CCCH-type containing 12A | 2 | 2 | ||||||||
MIRT461518 | EMC7 | ER membrane protein complex subunit 7 | 2 | 2 | ||||||||
MIRT466738 | SYNJ2BP | synaptojanin 2 binding protein | 2 | 2 | ||||||||
MIRT467651 | SLC7A1 | solute carrier family 7 member 1 | 2 | 2 | ||||||||
MIRT472998 | MRPS23 | mitochondrial ribosomal protein S23 | 2 | 4 | ||||||||
MIRT477911 | DUSP2 | dual specificity phosphatase 2 | 2 | 2 | ||||||||
MIRT480853 | BLCAP | bladder cancer associated protein | 2 | 2 | ||||||||
MIRT482890 | IAH1 | isoamyl acetate-hydrolyzing esterase 1 homolog | 2 | 4 | ||||||||
MIRT487295 | SLC38A9 | solute carrier family 38 member 9 | 2 | 2 | ||||||||
MIRT488494 | SFMBT2 | Scm like with four mbt domains 2 | 2 | 4 | ||||||||
MIRT489060 | STARD3 | StAR related lipid transfer domain containing 3 | 2 | 2 | ||||||||
MIRT491209 | MLLT1 | MLLT1, super elongation complex subunit | 2 | 4 | ||||||||
MIRT491479 | APC2 | APC2, WNT signaling pathway regulator | 2 | 8 | ||||||||
MIRT492558 | PRX | periaxin | 2 | 6 | ||||||||
MIRT495499 | SLC39A2 | solute carrier family 39 member 2 | 2 | 2 | ||||||||
MIRT496578 | ZNF280D | zinc finger protein 280D | 2 | 2 | ||||||||
MIRT496840 | KCNIP2 | potassium voltage-gated channel interacting protein 2 | 2 | 2 | ||||||||
MIRT497840 | CHD1 | chromodomain helicase DNA binding protein 1 | 2 | 2 | ||||||||
MIRT499396 | PLCG2 | phospholipase C gamma 2 | 2 | 7 | ||||||||
MIRT503237 | C16orf74 | chromosome 16 open reading frame 74 | 2 | 4 | ||||||||
MIRT512345 | ZNF665 | zinc finger protein 665 | 2 | 4 | ||||||||
MIRT512527 | ATCAY | ATCAY, caytaxin | 2 | 4 | ||||||||
MIRT513160 | PPIB | peptidylprolyl isomerase B | 2 | 2 | ||||||||
MIRT514493 | STOML1 | stomatin like 1 | 2 | 2 | ||||||||
MIRT517164 | SLC28A1 | solute carrier family 28 member 1 | 2 | 2 | ||||||||
MIRT520463 | TRPV2 | transient receptor potential cation channel subfamily V member 2 | 2 | 2 | ||||||||
MIRT524151 | DIP2A | disco interacting protein 2 homolog A | 2 | 2 | ||||||||
MIRT530324 | TNFRSF10D | TNF receptor superfamily member 10d | 2 | 2 | ||||||||
MIRT533747 | TMEM184B | transmembrane protein 184B | 2 | 2 | ||||||||
MIRT534259 | SLC12A7 | solute carrier family 12 member 7 | 2 | 2 | ||||||||
MIRT561273 | ZDHHC18 | zinc finger DHHC-type containing 18 | 2 | 2 | ||||||||
MIRT569126 | TMC5 | transmembrane channel like 5 | 2 | 4 | ||||||||
MIRT569937 | RAB8A | RAB8A, member RAS oncogene family | 2 | 2 | ||||||||
MIRT570073 | VPS8 | VPS8, CORVET complex subunit | 2 | 2 | ||||||||
MIRT570636 | KLF13 | Kruppel like factor 13 | 2 | 2 | ||||||||
MIRT571026 | CENPP | centromere protein P | 2 | 2 | ||||||||
MIRT573838 | ZWINT | ZW10 interacting kinetochore protein | 2 | 2 | ||||||||
MIRT574899 | Plcg2 | phospholipase C, gamma 2 | 2 | 5 | ||||||||
MIRT576070 | Poteg | POTE ankyrin domain family, member G | 2 | 2 | ||||||||
MIRT576753 | Tmem127 | transmembrane protein 127 | 2 | 2 | ||||||||
MIRT611795 | WNT9A | Wnt family member 9A | 2 | 2 | ||||||||
MIRT616756 | SVOP | SV2 related protein | 2 | 2 | ||||||||
MIRT630965 | NGDN | neuroguidin | 2 | 2 | ||||||||
MIRT634555 | LYVE1 | lymphatic vessel endothelial hyaluronan receptor 1 | 2 | 2 | ||||||||
MIRT638646 | GK5 | glycerol kinase 5 (putative) | 2 | 2 | ||||||||
MIRT639903 | SRGAP2 | SLIT-ROBO Rho GTPase activating protein 2 | 2 | 2 | ||||||||
MIRT640529 | TET3 | tet methylcytosine dioxygenase 3 | 2 | 4 | ||||||||
MIRT644529 | TMEM134 | transmembrane protein 134 | 2 | 2 | ||||||||
MIRT644887 | C2orf50 | chromosome 2 open reading frame 50 | 2 | 2 | ||||||||
MIRT647729 | CXCR2 | C-X-C motif chemokine receptor 2 | 2 | 2 | ||||||||
MIRT648086 | FAM192A | family with sequence similarity 192 member A | 2 | 2 | ||||||||
MIRT650808 | PGRMC1 | progesterone receptor membrane component 1 | 2 | 2 | ||||||||
MIRT660505 | ARPC2 | actin related protein 2/3 complex subunit 2 | 2 | 2 | ||||||||
MIRT667193 | NODAL | nodal growth differentiation factor | 2 | 2 | ||||||||
MIRT685675 | PSMB7 | proteasome subunit beta 7 | 2 | 2 | ||||||||
MIRT692710 | MEAF6 | MYST/Esa1 associated factor 6 | 2 | 2 | ||||||||
MIRT693598 | SLC39A1 | solute carrier family 39 member 1 | 2 | 2 | ||||||||
MIRT698059 | TRIOBP | TRIO and F-actin binding protein | 2 | 2 | ||||||||
MIRT698292 | TMEM2 | transmembrane protein 2 | 2 | 2 | ||||||||
MIRT702353 | KLHL26 | kelch like family member 26 | 2 | 2 | ||||||||
MIRT708623 | NUDT18 | nudix hydrolase 18 | 2 | 2 | ||||||||
MIRT714289 | KBTBD11 | kelch repeat and BTB domain containing 11 | 2 | 2 | ||||||||
MIRT714577 | WDR41 | WD repeat domain 41 | 2 | 2 | ||||||||
MIRT716734 | APOL6 | apolipoprotein L6 | 2 | 2 | ||||||||
MIRT718781 | RAC3 | Rac family small GTPase 3 | 2 | 2 | ||||||||
MIRT720973 | ZBTB43 | zinc finger and BTB domain containing 43 | 2 | 2 | ||||||||
MIRT720986 | TOM1 | target of myb1 membrane trafficking protein | 2 | 2 | ||||||||
MIRT721391 | LDLRAD4 | low density lipoprotein receptor class A domain containing 4 | 2 | 2 | ||||||||
MIRT722905 | COA4 | cytochrome c oxidase assembly factor 4 homolog | 2 | 2 | ||||||||
MIRT723205 | ZNRF1 | zinc and ring finger 1 | 2 | 2 | ||||||||
MIRT725431 | HIVEP3 | human immunodeficiency virus type I enhancer binding protein 3 | 2 | 2 |
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|